Mitochondrial-targeted ubiquinone: A potential treatment for COVID-19.
Med Hypotheses
; 144: 110161, 2020 Nov.
Article
in English
| MEDLINE | ID: covidwho-694471
ABSTRACT
Immune dysregulation characterized by T cell exhaustion and high level of inflammatory cytokines is associated with severe COVID-19. Figuring out the early event of immune dysregulation would provide a potential treatment for COVID-19. Recent evidence indicate that mitochondrial dysfunction participates in the development of COVID-19 and may be responsible for the dysregulated immune response. Mitochondrial-targeted ubiquinone (MitoQ), a mitochondrial-targeted antioxidant, shows beneficial effects on various diseases through improving mitochondrial dysfunction. We hypothesize that MitoQ could act as a potential treatment in COVID-19. MitoQ may alleviate cytokine storm and restore the function of exhausted T cells in COVID-19 patients through improving mitochondrial dysfunction. In this article, we provide evidence to support the use of MitoQ as a potential treatment or adjunct therapy in the context of COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Organophosphorus Compounds
/
Ubiquinone
/
COVID-19 Drug Treatment
/
Mitochondria
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Med Hypotheses
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS